Navigation Links
Novel technique demonstrates interactions between malaria parasite and HIV
Date:8/15/2012

The World Health Organization estimates that in 2011 there were 216 million cases of malaria and 34.2 million people living with HIV. These diseases particularly afflict sub-Saharan Africa, where large incidence of co-infection result in high mortality rates. Yet, in spite of this global pandemic, interactions between the parasite that causes malaria, Plasmodium falciparum, and HIV-1 are poorly understood. However, a new video article in JoVE, the Journal of Visualized Experiments, that describes a novel technique to study the interactions between HIV-1 and P. falciparum in cultured human cells, will allow scientists to explore different parameters of co-infection by the two microbes.

The study is led by Dr. David Richard of the Centre Hospitalier Universitaire de Quebec (CHUQ). Dr. Richard explains, "We don't know much about what is happening at the cellular level when HIV-1-infected immune cells encounter the malaria parasite. Results obtained from the few studies exploring the interaction of these two diseases are sometimes conflicting. We hope that our model will allow us to thoroughly dissect these interactions in a simplified system."

Each disease attacks a different component of human blood, thus disturbing normal immune function. P. falciparum infect red blood cells and cause fever, shivering, vomiting, or convulsions in patients. HIV-1 causes acquired immune deficiency syndrome (AIDS) by infecting components of the immune system, including macrophages and helper T cells, and then replicates and destroys the host cells. By studying co-infection at different phases of each disease in vitro, scientists can better understand how different stages of malaria infection and HIV reproduction affect the onset and severity of the other disease. As such, Dr. Richard and his laboratory present a technique that investigates how P. falciparum-infected red blood cells affect the replication of HIV-1 in monocyte-derived macrophages.

Dr. Richard points out that, "by publishing in JoVE, you really see what is happening in the experiment. The visual representation helps succinctly explain a long procedure, and gives you a fuller picture of the schematic complexity." He hopes that this publication will give the scientific community the tools to look at the interactions on a cellular level, which would be an initial step in improving the quality of life for individuals infected by these deadly diseases. "This protocol provides a tool to examine the interactions between P. falciparium and HIV," states JoVE editor Dr. Charlotte Frank Sage, "Publication of the protocol in JoVE will allow researchers around the world to see a detailed demonstration of this system which will help in bring the technology to their laboratories."


'/>"/>

Contact: Neal Moawed
neal.moawed@jove.com
617-765-0137
The Journal of Visualized Experiments
Source:Eurekalert  

Related medicine news :

1. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
2. Rutgers team discovers novel approach to stimulate immune cells
3. Novel drug candidates offer new route to controlling inflammation
4. Researchers present new findings for novel pancreatic cancer vaccine
5. Novel biomarkers reveal evidence of radiation exposure
6. VCU Massey Cancer Center sees potential in novel leukemia treatment
7. Study supports urate protection against Parkinsons disease, hints at novel mechanism
8. Novel Natural Sciences Repository Opens Web Portal
9. Novel Anti-Inflammatories May Offer a New Approach for the Treatment of Stroke
10. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
11. Novel radiation therapy safely treats prostate cancer and lowers the risk of recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel technique demonstrates interactions between malaria parasite and HIV
(Date:9/19/2017)... ... 2017 , ... The Davidson Institute for Talent Development will ... 27 at a reception in Washington D.C. The recipients received $50,000, $25,000 and ... “I am honored to be a Davidson Fellow Laureate,” said Rishab Gargeya, a ...
(Date:9/19/2017)... Brook, IL (PRWEB) , ... September 19, 2017 ... ... are significantly and positively linked to the Certified Emergency Nurse (CEN®) certification ... for Emergency Nursing (BCEN). The value of certification study, conducted by the Human ...
(Date:9/18/2017)... (PRWEB) , ... September 19, 2017 , ... ... Asia Pacific’s protein ingredient market , expected to grow at the fastest CAGR ... Sullivan sharing the ‘Global Food Protein Trends & Growth Opportunities in Asia’ – ...
(Date:9/18/2017)... ... September 18, 2017 , ... ... the finance role on the executive team adding a Chief Financial Officer following ... independent company. This expansion will support the strategic growth strategy Aegis has defined ...
(Date:9/18/2017)... Fort Lee, NJ (PRWEB) , ... September 18, 2017 , ... ... state’s history, CareOne, a New jersey based company, has launched an aid effort focused ... Irma as it battered the state over two days and left thousands homeless and ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)...   OrthoAtlanta has been named the official orthopedic ... (AFHC) for the 2018 College Football Playoff (CFP) National Championship ... Stadium in Atlanta, Georgia . OrthoAtlanta is ... campaign, participating in many activities leading up to, and including ... ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
Breaking Medicine Technology: